Promacta 12.5 mg Oral Tablet
RxNorm 1245003
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1245003 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Promacta 12.5 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
Eltrombopag 12.5 mg Oral Tablet [Promacta]
(Atom ID: 4248559)
SYPrescribable
Synonym (SY):
Promacta (as eltrombopag olamine) 12.5 mg Oral Tablet
(Atom ID: 8251115)
PSNPrescribable
Prescribable Name (PSN):
Promacta 12.5 mg Oral Tablet
(Atom ID: 6364995)
SYPrescribable
Synonym (SY):
Promacta 12.5 mg Oral Tablet
(Atom ID: 4226801)
Patient Education
Eltrombopag
Eltrombopag is used to increase the number of platelets (cells that help the blood clot) to decrease the risk of bleeding in adults and children 1 year of age and older who have chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood) and who have not been helped or cannot be treated with other treatments, including medications or surgery to remove the spleen. Eltrombopag is also used to increase the number of platelets in people who have hepatitis C (a viral infection that may damage the liver) so that they can begin and continue treatment with interferon (Peginterferon, Pegintron, others) and ribavirin (Rebetol). Eltrombopag is also used in combination with other medications to treat aplastic anemia (condition in which the body does not make enough new blood cells) in adults and children 2 years of age and older. It is also used to treat aplastic anemia in adults who have not been helped with other medications. Eltrombopag is used to increase the number of platelets enough to decrease the risk of bleeding in people with ITP or aplastic anemia, or to allow treatment with interferon and ribavirin in people with hepatitis C. However it is not used to increase the number of platelets to a normal level. Eltrombopag should not be used to treat people who have low numbers of platelets due to conditions other than ITP, hepatitis C, or aplastic anemia. Eltrombopag is in a class of medications called thrombopoietin receptor agonists. It works by causing the cells in the bone marrow to produce more platelets.
[Learn More]
* Please review the disclaimer below.